Universal allogeneic CAR-T
Off-the-shelf CAR and NK cells edited from healthy donors - one manufacture, many patients. The table carries three vendors with ledger-backed dossiers; Allogene and Caribou are named in the note until ledgers exist.
1 · What it gives
Autologous CAR-T made the category and capped it: every dose is a patient-specific manufacturing campaign, so the therapy arrives late and priced like a bespoke process. Universal allogeneic CAR-T removes the patient from the manufacturing loop — healthy-donor or iPSC-derived cells are gene-edited to delete the traits that would make them attack their host (and be attacked), then banked as off-the-shelf doses. The edits are the technology: TALEN knockout of the T-cell receptor at Cellectis, CRISPR editing at CRISPR Therapeutics, and cord-blood-derived NK lines at Artiva, each holding its programmed state through expansion. The corpus’s ledger evidence marks the distance from concept to clinic: Cellectis holds an FDA RMAT designation (June 2026) for lasme-cel (UCART22) in relapsed/refractory B-ALL with a Phase 1 reporting a 100 percent response rate; CRISPR Therapeutics manufactures end-to-end in Framingham and holds the field’s first approved CRISPR medicine; Artiva raised $741.9 million and runs a cGMP San Diego center sized to treat over 1,000 autoimmunity patients annually. The value chain is a banking chain — one manufacture, thousands of doses, and a cold chain that replaces apheresis logistics with inventory.
Key directions of universal allogeneic CAR-T:
- TALEN-edited allogeneic pipelines (UCART Class): Cellectis’s UCART22 carries FDA RMAT designation in r/r B-ALL; one production batch yields hundreds of doses, scalable to thousands.
- CRISPR-edited cell platforms (Casgevy to CAR): CRISPR Therapeutics pairs the first approved CRISPR medicine with a wholly-owned GMP facility in Framingham, Massachusetts and end-to-end cell-therapy production.
- Off-the-shelf NK (AlloNK and AB-101): Artiva Biotherapeutics advances allogeneic NK with FDA Fast Track in refractory rheumatoid arthritis and capacity above 1,000 patients per year.
- Donor-to-bank manufacturing (Centralized Supply): Paris, Raleigh and New York facilities at Cellectis — 55,000 and 82,000 square-foot sites — turn donor cells into inventoried therapy.
Sectoral value chain#
[healthy donor / iPSC line] ──> [gene editing] ──> [expansion, banking]
│
(knockout: self vs host attack)
▼
[many patients, one batch] <── [release, cryostorage] <── [quality characterization]
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Donor sourcing | healthy donor apheresis or master iPSC line | In: screened donors. Out: starting cell material. |
| Gene editing | TCR/HLA and safety knockout | In: starting cells. Out: edited, allogeneic-safe cells. |
| Engineering and expansion | CAR/NK receptor integration, scale-up | In: edited cells. Out: therapeutic cell batches. |
| Banking and cryostorage | inventory of released doses | In: batches. Out: off-the-shelf dose bank. |
| Release testing | identity, potency, sterility per lot | In: doses. Out: GMP-released product. |
| Clinical deployment | lymphodepletion plus infusion | In: released doses. Out: treated patients without manufacturing delay. |
Cross-cutting technologies of the sector:
- Gene-editing reagents (TALEN/CRISPR Platforms): the editor choice sets IP, specificity and regulatory precedent.
- Cryostorage networks (Dose Banking): liquid-nitrogen inventory that substitutes for apheresis-to-infusion logistics.
- Alloreactivity analytics (GVHD/Rejection Assays): the tests proving an edited cell will not attack its host or be rejected.
2 · What it replaces 0 · matched by industry
No graded substitution linked yet.
3 · How to implement 6 steps
- 1Donor sourcingScreened healthy donors or a master iPSC line supply starting cells whose variability is bounded before editing begins.
- 2Gene editingTALEN or CRISPR nucleases knock out TCR and HLA markers, converting donor cells into cells the patient’s immune system will tolerate.
- 3Engineering and expansionFermentation & cultivationCAR or NK receptor engineering follows, and the edited cells expand to batch scale — hundreds to thousands of doses per manufacture.Who can do this step matched automatically✓ ISO 9001 500 m3“Technology: microbial fermentation with ~500 m3 fermentation capacity; 15+ patents; developed/upscaled probiotic production technologies.”Cell AgriTech Malaysia5,000 L industrial scale“We design and fabricate our own stainless-steel bioreactors, automation systems, and harvesting modules, which lower CAPEX and OPEX by more than 80% compared to pharma-grade …”XIKE Enzymes China12,000 tons industrial scale“History and scale: 20 years in operation; two production bases (Fuzhou and Gutian, Fujian) with 600 metric-ton fermentation capacity and 20,000 metric tons annual output; …”Fermelanta Japan3,000 L pilot scale“We transform the traditional supply chain depending on agricultural cultivation and extraction into a next-gen microbial fermentation process that can offer low-cost and …”RWDC Industries Singaporeindustrial scale“Using a proprietary microbial fermentation process, we produce PHA (polyhydroxyalkanoate), a naturally occurring biopolymer made from plant-based oils.”
- 4Banking and cryostorageReleased batches enter liquid-nitrogen inventory, converting cell therapy from a campaign into stock.
- 5Release testingTesting & analyticsIdentity, potency and sterility are certified per lot, since every patient receives the same banked product.
- 6Clinical deploymentPatients receive lymphodepletion and infusion without waiting on manufacturing — the delay autologous therapy could not remove.
4 · Who delivers
Matched suppliers (matched automatically)
| Johnson & Johnson | United States | Producer | active |
| Ingenio Risaralda S.A. | Colombia | Producer | active |
| Ipiranga Agroindustrial S/A | Brazil | Producer | active |
| Corporación Montelimar | Nicaragua | Producer | active |
| Kolon Industries | South Korea | Producer | active |
| Pantaleon | Guatemala | Producer | active |
| Alcoholes del Istmo Internacional SA | Panama | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Cellectis | 🇫🇷 France | Allogeneic TALEN-edited UCART22 | FDA RMAT June 2026; Phase 1 100% response; Paris/Raleigh/New York sites | Clinical |
| CRISPR Therapeutics | 🇨🇭 Switzerland | CRISPR cell-therapy portfolio (Casgevy) | First approved CRISPR medicine; GMP Framingham; end-to-end production | Commercial |
| Artiva Biotherapeutics | 🇺🇸 USA | Allogeneic NK (AB-101), AlloNK | FDA Fast Track (refractory RA); $741.9 m raised; >1,000 patients/yr capacity | Clinical |
5 · Rules & route to market
United States
The US is the regulatory fast lane: FDA RMAT designations and Fast Track grants are the milestones the allogeneic race times itself against.
RMAT designations, Fast Track for AlloNK, Framingham GMP#
- Cellectis Raleigh and New York sites: an 82,000 sq ft North Carolina facility and a 25,000 sq ft New York site anchor US production beside the Paris headquarters.
- Artiva Biotherapeutics (San Diego): $741.9 million raised through June 2026, a 9,000 sq ft cGMP cell-production center, 106 employees, and capacity above 1,000 autoimmunity patients annually.
- CRISPR Therapeutics Framingham: wholly-owned GMP manufacturing supporting the cell-therapy portfolio end to end.
European Union
Europe contributes the edited-cell pioneer and the ATMP framework — EMA’s advanced-therapy class is the regulatory template allogeneic products are filed under.
Cellectis Paris GMP, ATMP classification, EMA filing track#
- Cellectis Paris (55,000 sq ft): the founding allogeneic developer manufactures beside its Sorbonne-campus roots, with one batch producing hundreds of doses scalable to thousands.
- ATMP regulation: allogeneic edited cells file as advanced-therapy medicinal products — the EMA class the whole sector’s European strategy assumes.
- Swiss-registered portfolios: CRISPR Therapeutics’ European presence runs through Swiss-domiciled listing and EU clinical sites.
China
China runs a parallel allogeneic and NK development track under NMPA review; the corpus’s ledger depth there has not reached this node yet, so this section records the structure rather than vendor claims.
NMPA cell-therapy pathways, domestic NK pipelines, hospital networks#
- NMPA cell-therapy review: allogeneic candidates follow the same category rules as autologous CAR-T, with hospital-network trials as the throughput engine.
- Domestic NK lines: cord-blood and peripheral-blood NK programs advance alongside CAR-T.
- Manufacturing localization: GMP capacity for edited-cell therapies is being built domestically to mirror the US and EU footprint.
6 · Money: tenders & grants
| Grant | Advancing bio-printing of living cells for regenerative medicine European Commission · EU | Sep 22, 2027 303 days |
7 · Tech stack & innovations
The stack is editing plus banking: delete what makes a donor cell dangerous, engineer what makes it therapeutic, and hold it ready.
- TALEN knockout editing (UCART Platform):
- TALEN nucleases knock out the T-cell receptor to stop graft-versus-host and HLA to delay rejection.
- case: lasme-cel (UCART22) — FDA RMAT designation in June 2026 after a Phase 1 with 100 percent response.
- CRISPR editing with owned manufacturing (Casgevy Lineage):
- CRISPR-edited cells manufactured end to end in a wholly-owned Framingham GMP facility.
- case: Casgevy — the first CRISPR medicine approved, with 2026 expansion to children as young as two.
- Cord-blood NK banking (Off-the-Shelf NK):
- allogeneic NK lines skip T-cell rejection engineering entirely and bank doses for oncology and autoimmunity.
- case: Artiva’s AB-101/AlloNK — Fast Track in refractory rheumatoid arthritis, capacity above 1,000 patients a year.
Sources 3 · 0 independent · 3 producer sites
Producers' own sites 3
- allsci.com · finance.yahoo.com · ml.globenewswire.com · www.cellectis.com · www.cellectis.com · www.cellectis.com · www.cellectis.com · www.cellectis.com producer checked 2026-09-18
- altindex.com · crisprtx.com · crisprtx.gcs-web.com · crisprtx.gcs-web.com · ir.crisprtx.com · ir.crisprtx.com · last10k.com · pmc.ncbi.nlm.nih.gov · profit.com · www.fda.gov · www.sec.gov producer checked 2026-09-18
- investors.artivabio.com · s203.q4cdn.com · stockanalysis.com · www.artivabio.com · www.artivabio.com · www.sec.gov · www.stocktitan.net producer checked 2026-09-18